Disease	Lung cancer – NSCLC
Stage of Disease/Treatment	Metastatic/advanced
Prior Therapy	None
Type of Study – 1	Phase I
Type of Study – 2	Modified toxicity probability interval
Primary Endpoint	Maximum tolerated dose
Secondary Endpoint	Recommended phase II dose
Additional Details of Endpoints or Study Design	Objective responses assessed by RECIST version 1.1
Investigator's Analysis	Active, but patient numbers too low for accurate comparison